Close Menu

OHSU

A new GeoMx Digital Spatial Profiler assay will have up to 30 protein targets and will be validated for potential use as a laboratory-developed test.

At the ASHG conference, a researcher described efforts to sequence SARS-CoV-2 genomes from Oregon to investigate introductions, super-spreader events, and viral biology.

Ymir Genomics and OHSU will share in any value created by the biomarkers and will jointly publish and validate the biomarkers in a large-scale multi-center study.

In PNAS this week: genetic variants linked to a pediatric periodic fever syndrome, TERT promoter mutations influencing BRAF and MEK inhibitor response, and more.

At the Biology of Genomes virtual conference last week, several presentations focused on single-cell and spatial genomics data sets and how they could be complementary.

In PNAS this week: single-cell RNA sequencing study of pancreatic duct cells, sequencing of viruses affecting honey bees, and more.

CRISPR for Blindness

According to the Associated Press, a patient has undergone gene editing to treat an inherited form of blindness.

Investigators have developed an approach called RAMP-Seq in which targeted radiation of a suspicious lesion vastly increase levels ctDNA, aiding detection and allowing genotyping. 

With the participation of five cancer centers and clinics, Taproot is hoping to build a national, prospective data registry that is much needed but has been difficult to advance to date.

Within the master observational trial, the organizations have agreed to prospectively collect real world data and ultimately build a national oncology database.

Pages

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

The New York Times reports that a new viral variant of concern has been identified in New York City.

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.